echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > The pharmaceutical company expects to double the number of R&D teams by 2023

    The pharmaceutical company expects to double the number of R&D teams by 2023

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 24, Bide Pharma said on the investor interactive platform that the company currently has a 5,300-square-meter R&D and production center in Songjiang, with a R&D team of about 130 people
    .
    It is expected that in 2023, the R&D team will be expanded to about 260 people, and about 5,000 square meters of R&D + QC laboratory will be added to further improve R&D capabilities
    .

     
    According to the data, Bede Pharma focuses on the front end of the new drug R&D industry chain, relying on the core business of R&D, design, production and sales of drug molecular building blocks, and can provide new drug R&D institutions with novel structure and diverse functions of drug molecular building blocks and scientific reagents and other products
    .

     
    In recent years, with the support of favorable policies, the addition of talents, the increase in capital, and the continuous increase in R&D investment of pharmaceutical companies, the global research and development of new drugs is hot, and the R&D and production industry of drug molecular building blocks has also ushered in good prospects
    .
    According to industry estimates, the global market size of drug molecular building blocks was $44.
    1 billion in 2020 and is expected to reach $54.
    6 billion
    by 2026.
    However, in the field of molecular building blocks in China, the number of pharmaceutical companies with strength is still relatively small, and the industry believes that domestic alternative enterprises with R&D information platform innovation are expected to gain opportunities
    .

     
    It is understood that after years of development, Bide Pharma has a comprehensive core technology related to drug molecular building blocks, forming a core technical system represented by drug molecular building block R & D design, customized synthesis, molecular structure confirmation, purity testing and purification, etc.
    , and has the ability to provide more than 300,000 drug molecular building blocks with novel structure and diverse functions to new drug research and development institutions, including more than 70,000 kinds of standing drug molecular building blocks in the spot library
    .

     
    On May 5 this year, Bede Pharma held its first meeting, and planned to raise 434 million yuan for the regional center project of drug molecular building blocks, the research and development laboratory project and supplementary working capital
    .

     
    According to the strategic objectives disclosed in the prospectus, BIDE will take people's life and health as its basic values, comprehensively serve new drug research and development, continue to pay close attention to the development trend of the global biomedical industry, give full play to existing technical advantages and resource advantages, continue to deepen the new drug research and development services and industrial application market, and further increase the comprehensive ability
    to serve global new drug research and development institutions through continuous research and development innovation, together with customers and suppliers.

     
    According to the third quarterly report of 2022, the company's main revenue was 589 million yuan, a year-on-year increase of 37.
    95%; the net profit attributable to the parent was 98.
    0199 million yuan, an increase of 46.
    95% over the same period last year; Deducted non-net profit of 95.
    8118 million yuan, up 46.
    49% from the same period last year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 220 million yuan, a year-on-year increase of 38.
    87%; The net profit attributable to the parent in a single quarter was 38.
    844 million yuan, a year-on-year increase of 65.
    44%.


     
    TF Securities recently said in a research report on Bede Pharmaceutical that the company focuses on the business of drug molecular building blocks and scientific reagents, with outstanding variety richness and quality/price advantages, and the penetration rate of downstream new drug R&D customers has gradually increased; Forward-looking strategic layout in the international market, global multi-center layout in the United States, India, Germany and other places, rich customer resources at home and abroad
    .
    The bank believes that the company's brand/variety/warehousing/cost all-round competitive barriers continue to be consolidated, can quickly respond to global customer needs, coupled with the vigorous development of new drug research and development and pharmaceutical outsourcing industries, the company's performance is expected to maintain stable growth
    .

     
    As of the close on November 24, Bede Pharmaceutical edged up 0.
    93%, with a quotation of 89.
    23 yuan, a turnover of 26.
    9 million, a turnover rate of 2.
    25%, a price-to-earnings (TTM) of 44.
    94, and a total market value of 5.
    792 billion
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.